Payer Policy

GLP-1 Prior Authorization by Payer in 2026: UHC, Aetna, Cigna, BCBS & Medicare

GLP-1 prior authorization criteria for every major payer in 2026 — exact A1c thresholds, BMI requirements, step-therapy rules, covered drugs vs excluded drugs, and how to write an LMN that gets approved on the first submission.

RxCheckUp Clinical Team · 2026-06-01 · 15 min read

Why GLP-1 Prior Authorization Is the Hardest PA Category in 2026

GLP-1 receptor agonists have become the single highest-volume prior authorization drug class in the United States. As of 2026, semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound) together account for more PA submissions per month than any other drug class — and denial rates remain among the highest in pharmacy, routinely exceeding 30% on first submission for weight-loss indications.

The difficulty stems from several intersecting forces: (1) payers sharply distinguish between diabetes and obesity indications even when the clinical drug is identical; (2) benefit design varies radically across employer, individual, Medicare, and Medicaid lines — some plans cover obesity treatment, most do not; (3) formulary strategy has shifted rapidly as manufacturers negotiated preferred placement deals, making the "right" GLP-1 different for every plan; and (4) step-therapy and lifestyle program requirements vary by payer and have changed multiple times as clinical evidence evolved.

This guide breaks down GLP-1 prior authorization requirements for each major commercial payer and Medicare as of mid-2026, with the specific criteria, documentation requirements, and appeal strategies you need to get approvals on first submission.

GLP-1 Indications: Diabetes vs Obesity — the Critical Distinction

Before reviewing payer-specific criteria, it is essential to understand how payers and plan designs categorize GLP-1 drugs, because the same active molecule can receive completely different coverage treatment depending on its branded indication.

✓ Diabetes indication (T2DM glycemic control): Ozempic (semaglutide 0.5/1/2 mg weekly), Mounjaro (tirzepatide 2.5–15 mg weekly), Rybelsus (oral semaglutide), Trulicity (dulaglutide), Victoza (liraglutide), Byetta/Bydureon (exenatide) — these are covered under pharmacy benefits for T2DM and follow diabetes PA criteria (A1c thresholds, prior metformin, step therapy)
✓ Obesity/weight management indication: Wegovy (semaglutide 2.4 mg weekly), Zepbound (tirzepatide 2.5–15 mg weekly), Saxenda (liraglutide 3 mg daily), Qsymia, Contrave — these require obesity PA criteria (BMI ≥30 or ≥27 with comorbidity, behavioral program, prior weight-loss agent trials) and are subject to benefit exclusions
✓ Critical problem: many employers explicitly exclude "weight loss drugs" in their plan documents, which means Wegovy and Zepbound may receive a benefit exclusion denial rather than a PA denial — and benefit exclusions cannot be appealed on medical necessity grounds (they require a plan amendment)
✓ Dual indication overlap: Mounjaro is FDA-approved only for T2DM but is prescribed off-label for obesity — payers follow the labeled indication; Ozempic is approved for T2DM and cardiovascular risk reduction but not obesity (Wegovy is the obesity formulation); submitting Ozempic for obesity management is an off-label request requiring different justification

UnitedHealthcare GLP-1 Prior Authorization Criteria 2026

UnitedHealthcare is the largest commercial payer by membership and sets a high bar for GLP-1 approvals. UHC uses OptumRx as its PBM for most commercial and employer accounts, with PA reviewed through the Availity portal.

✓ Diabetes indication (Ozempic, Mounjaro, Rybelsus): A1c ≥7.5% required at baseline; metformin trial documented (or contraindication/intolerance); may require trial of a formulary-preferred GLP-1 or SGLT-2 inhibitor first depending on formulary tier; A1c labs must be within the prior 6 months
✓ Obesity indication (Wegovy, Zepbound): BMI ≥30 kg/m² OR BMI ≥27 with at least one weight-related comorbidity (T2DM, hypertension, hyperlipidemia, OSA, CVD); documented enrollment in or completion of a structured weight management program (e.g., intensive behavioral therapy ≥12 visits); prior pharmacotherapy trial with a non-GLP-1 agent may be required depending on the employer plan design
✓ Coverage depends entirely on the employer group plan document — many UHC-administered employer plans exclude weight-loss drugs outright; verify benefit inclusion before submitting PA
✓ SELECT trial data (semaglutide cardiovascular outcomes in non-diabetic obese patients) has expanded coverage criteria for some plans; cite CVOT data if the patient has established CVD
✓ UHC gold carding: practices with ≥90% approval rates over 12 months may qualify for PA exemptions for certain GLP-1 indications

Aetna GLP-1 Prior Authorization Criteria 2026

Aetna publishes detailed Clinical Policy Bulletins (CPBs) for each GLP-1 agent. Aetna's criteria are generally well-defined and can be found in CPB 0617 (GLP-1 agonists) and CPB 0578 (obesity pharmacotherapy). The CPBs specify exact thresholds and documentation requirements.

✓ Diabetes (CPB 0617): A1c ≥7% to ≥8% depending on agent; metformin at maximally tolerated dose required (or documented contraindication/intolerance); GLP-1 preferred list hierarchy — Trulicity may be preferred over Ozempic/Mounjaro depending on formulary year
✓ Obesity (CPB 0578): BMI ≥30 OR ≥27 with comorbidity; documentation of at least 6 months of structured diet and exercise counseling within the prior year; prior pharmacotherapy trial (orlistat, phentermine, combination agent) preferred but may be waived with clinical justification
✓ Cardiovascular indication (Wegovy for MACE reduction, SELECT trial): Aetna has updated CPB criteria for 2026 to recognize Wegovy's FDA approval for cardiovascular risk reduction in obese/overweight patients with established CVD — separate coverage path without obesity benefit exclusion issues
✓ Aetna requires the CPB number be cited in the PA submission — include "CPB 0617" or "CPB 0578" explicitly in the LMN to facilitate expedited review
✓ Peer-to-peer: Aetna PA line 1-800-537-9384; peer-to-peer within 14 days of denial notice

Cigna GLP-1 Prior Authorization Criteria 2026

Cigna uses coverage policies (CP) to govern GLP-1 PA. Cigna's pharmacy PA is managed through Express Scripts (ESI) for most commercial accounts. Cigna has been among the more restrictive major payers for obesity-indication GLP-1 approvals.

✓ Diabetes: A1c ≥7.5%; metformin required (minimum 3-month trial at ≥1000 mg/day unless contraindicated); preferred formulary GLP-1 trial required in many plans (Trulicity or Victoza before Ozempic in some formularies)
✓ Obesity: BMI ≥30 OR ≥27 with comorbidity; Cigna's Healthy Rewards or equivalent wellness program participation may be required; most Cigna employer plans do NOT include obesity drug coverage — confirm benefit inclusion first
✓ Cigna Express Scripts formulary: Wegovy and Zepbound placement varies by year and employer plan — check the current ESI formulary before submitting; some plans have moved to Zepbound-preferred due to manufacturer contracting
✓ Denial appeal: cite Cigna Coverage Policy number in appeal letters; Cigna peer-to-peer requests via 1-800-88CIGNA (882-4462) within 30 days of denial
✓ Cigna ExclusivelyCare / HDIP plans: often have separate drug benefit riders — GLP-1 obesity coverage may be on a separate rider; verify prior to submission

Blue Cross Blue Shield (Anthem/Elevance Health) GLP-1 Criteria 2026

BCBS plans are decentralized — each state affiliate publishes its own medical policies. However, Anthem/Elevance plans (operating in 14 states) follow IngenioRx PBM criteria, and most BCBS national accounts follow FEP (Federal Employee Program) Blue criteria when on federal plans.

✓ Anthem/Elevance (IngenioRx): diabetes criteria generally follow ADA guidelines with A1c ≥7%; obesity criteria include BMI ≥30 and require a behavioral weight management program (minimum 6 months); some Anthem plans now cover SELECT trial-indicated Wegovy for established CVD without the behavioral program requirement
✓ FEP Blue (Federal Employee Program): FEP Blue covers Wegovy and Zepbound for obesity with BMI ≥30 or ≥27 + comorbidity — one of the most comprehensive GLP-1 obesity coverages among large payers; A1c and diabetes criteria follow ADA standard
✓ Independent BCBS affiliates (BCBS Michigan, Texas, Illinois, etc.): policies vary significantly — always look up the specific affiliate's medical policy by number; most BCBS affiliates have updated GLP-1 policies in 2025-2026 following SELECT trial data
✓ BCBS federal (FEP) advantage: federal employees and retirees on FEP Blue have obesity drug coverage as a core benefit — the most straightforward GLP-1 PA category for this population

Medicare GLP-1 Coverage in 2026: Part D and Medicare Advantage

Traditional Medicare Part D has historically excluded weight-loss drugs from coverage under the Social Security Act, but this restriction has been evolving rapidly in 2026 following the Treat and Reduce Obesity Act (TROA) implementation and CMS regulatory changes.

✓ Traditional Medicare Part D — diabetes: Ozempic, Mounjaro, Rybelsus, Trulicity are covered as Part D drugs for T2DM with standard PA requirements (A1c ≥7%, metformin trial, formulary tier placement)
✓ Traditional Medicare Part D — obesity: Wegovy is now coverable under Part D for the cardiovascular indication (SELECT trial) in patients with established CVD and BMI ≥27 — this follows CMS guidance issued January 2024; obesity-only indication (without CVD) still faces coverage exclusion in most Part D plans through 2026
✓ Medicare Advantage: individual MA plans may add supplemental obesity drug coverage; verify plan-specific benefit with the MA plan — coverage is increasingly available in competitive Medicare Advantage markets
✓ Medicare Part B: GLP-1 agents are generally not covered under Part B (physician-administered drugs) because they are self-administered; exception may apply for homebound patients in limited circumstances
✓ Low-income subsidy (LIS/Extra Help): LIS beneficiaries generally face no formulary tier discrimination — the plan must cover the drug if it has a PA; this can be leveraged in PA strategy for LIS-eligible patients
✓ Donut hole / catastrophic phase: GLP-1 costs often push Medicare Part D patients into the catastrophic coverage phase by mid-year — document cost burden in LMN for continuity-of-care appeals

Medicaid GLP-1 Coverage 2026

Medicaid GLP-1 coverage is highly state-dependent and has been subject to significant policy flux following federal guidance changes. Key patterns as of mid-2026:

✓ Diabetes: most state Medicaid programs cover Ozempic, Mounjaro, and Rybelsus for T2DM with PA requirements (A1c thresholds, metformin first, prescriber restrictions in some states)
✓ Obesity/weight management: coverage for Wegovy and Zepbound for obesity is available in approximately 35 states as of 2026 following CMS's finalized rule allowing states to include anti-obesity drugs in Medicaid benefits; states that opted in include CA, NY, IL, CO, MA, WA, OR, and others; states without coverage: many southern and central states (TX, FL, GA, AL remain excluded)
✓ Medicaid managed care: if the state contracts with managed care organizations (MCOs), the MCO's PA requirements apply — which may be more or less restrictive than the state fee-for-service criteria; verify with the specific MCO
✓ Prior authorization restrictions: some state Medicaid programs require specialty prescriber (endocrinologist) for GLP-1 obesity indications; check state-specific PDL (Preferred Drug List)

What a GLP-1 Letter of Medical Necessity Must Include

A high-quality GLP-1 LMN reduces first-pass denial rates from 30%+ to under 10% when it hits all the required elements. The documentation checklist varies slightly by payer and indication:

✓ Diagnosis: ICD-10 code with maximum specificity — E11.9 (T2DM without complications) is weak; E11.65 (T2DM with hyperglycemia) or E11.69 (T2DM with other specified complications) with supporting labs is stronger; for obesity use E66.01 (morbid obesity) or E66.09 (other obesity) with comorbidity codes
✓ Labs: HbA1c within 6 months (for T2DM); current BMI with height/weight from a clinical note within 90 days (for obesity); lipid panel, fasting glucose, and blood pressure if comorbidities are relevant
✓ Prior therapy: metformin dose and duration (or contraindication with lab/clinical documentation); for obesity: prior weight-loss pharmacotherapy trials with drug, dose, duration, and reason for discontinuation
✓ Behavioral program: enrollment confirmation letter or provider attestation for programs requiring lifestyle documentation — include program name and participation dates
✓ Cardiovascular history: for SELECT-indication Wegovy, document ASCVD history (prior MI, stroke, PAD, or coronary revascularization) with dates
✓ Payer-specific CPB/policy citation: include the payer's clinical policy number in the opening paragraph ("This request meets the criteria outlined in Aetna CPB 0617 as follows...")
✓ Prescriber information: endocrinologist or primary care with diabetes management focus; some payers require specialist attestation for obesity indication

Common GLP-1 Denial Reasons and How to Beat Them

Despite high initial denial rates, most GLP-1 denials are reversible on first appeal. The most common denial reasons and their fixes:

✓ "Benefit exclusion — weight-loss drugs not covered": this is NOT a PA denial; confirm whether it is a plan-level exclusion (requires plan amendment) or a formulary tier issue (appealable); for Wegovy cardiovascular indication, explicitly cite the SELECT trial FDA supplement and CMS coverage guidance — this can overcome a plan-level obesity exclusion
✓ "Step therapy not complete — preferred GLP-1 required": identify the plan's preferred GLP-1, submit a formulary exception if the preferred agent is contraindicated, not tolerated, or previously failed; include dates and doses of any prior GLP-1 trial
✓ "A1c criterion not met": if A1c is borderline, include FASTING glucose, post-prandial glucose monitoring data, or CGM-derived time-in-range data to supplement the clinical picture; also document duration of diabetes and inadequate control on current regimen
✓ "Behavioral program not completed": obtain retroactive documentation of any dietary counseling, nutrition visits, or fitness program participation; primary care counseling notes (CPT 99401-99404) may satisfy this requirement if they document obesity-related lifestyle counseling
✓ "Medical necessity not established for obesity": cite SELECT trial data (CV outcomes), SURMOUNT trial data (tirzepatide), and the 2025 AHA/ACC Obesity Guideline that classifies obesity as a chronic disease requiring pharmacotherapy alongside lifestyle modification

How RxCheckUp Handles GLP-1 Prior Authorization

RxCheckUp generates GLP-1 LMNs that are pre-populated with the specific payer's current criteria — A1c threshold, BMI cutoffs, step-therapy sequence, behavioral program language, and policy citation — reducing the most common documentation gaps that cause first-pass denials.

For the cardiovascular indication (Wegovy/SELECT), RxCheckUp includes the specific SELECT trial citation and FDA labeling language that aligns with the CMS coverage determination, helping distinguish cardiovascular-eligible patients from standard obesity requests. For Medicare patients, it flags the cardiovascular eligibility pathway automatically based on the patient's CVD diagnosis codes.